An AI-driven review of oncology trials reveals that diversity progress over 30 years is largely an illusion driven by Asian enrollment growth.
Rahman Olusoji, MBBS
Advertisement
Articles by Rahman Olusoji, MBBS
Advertisement
An AI-driven review of oncology trials reveals that diversity progress over 30 years is largely an illusion driven by Asian enrollment growth.